Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

N Engl J Med. 2022 Jun 2;386(22):2112-2119. doi: 10.1056/NEJMoa2119662.


A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×109 autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02-restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors. The patient had regression of visceral metastases (overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1); the response was ongoing at 6 months. The engineered T cells constituted more than 2% of all the circulating peripheral-blood T cells 6 months after the cell transfer. In this patient, TCR gene therapy targeting the KRAS G12D driver mutation mediated the objective regression of metastatic pancreatic cancer. (Funded by the Providence Portland Medical Foundation.).

MeSH terms

  • Genes, T-Cell Receptor / genetics
  • Genetic Therapy* / methods
  • Humans
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / pathology
  • Pancreatic Neoplasms* / therapy
  • Proto-Oncogene Proteins p21(ras)* / genetics
  • Receptors, Antigen, T-Cell* / genetics
  • Receptors, Antigen, T-Cell* / therapeutic use


  • KRAS protein, human
  • Receptors, Antigen, T-Cell
  • Proto-Oncogene Proteins p21(ras)